0001144204-16-104957.txt : 20160526 0001144204-16-104957.hdr.sgml : 20160526 20160526080039 ACCESSION NUMBER: 0001144204-16-104957 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160526 FILED AS OF DATE: 20160526 DATE AS OF CHANGE: 20160526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galmed Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001595353 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981147233 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36345 FILM NUMBER: 161676277 BUSINESS ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 BUSINESS PHONE: 97236938448 MAIL ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 6-K 1 v440907_6k.htm FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

For the Month of May 2016

001-36345
(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

16 Tiomkin St.

Tel Aviv, 6578315, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

On May 25, 2016, Galmed Pharmaceuticals Ltd. held an Annual General Meeting of Shareholders (the "Meeting"). At the Meeting, the Company's shareholders voted on proposals to (i) re-elect Mr. Allen Baharaff as Class II director to serve as a member of the Board until the annual general meeting to be held in 2019; (ii) re-elect Mr. Shmuel Nir as Class I director to serve as a member of the Board until the annual general meeting to be held in 2018; (iii) approve an acceleration and an extension of exercise period of options granted to Dr. Maya Halpern; (iv) approve an amendment to the terms of office and employment of the Company’s President and Chief Executive Officer, Mr. Allen Baharaff; (v) approve an annual cash bonus and related objectives and terms thereof for 2016 for Mr. Allen Baharaff; (vi) approve the grant of equity awards to Mr. Allen Baharaff; (vii) re-approve the grant of equity awards to Mr. Allen Baharaff and Mr. Chaim Hurvitz, chairperson of the Board, for the year 2015; (viii) approve the grant of equity awards to non-management members of the Board; (ix) appoint Brightman Almagor Zohar & Co., a member firm of Deloitte Touche Tohmatsu Limited, as the Company’s independent registered public accounting firm until the 2017 annual meeting of shareholders, each as described in the proxy statement for the Meeting filed by the Company with the Securities and Exchange Commission as an exhibit to the Company's report on Form 6-K on April 20, 2016. The proposals brought before the shareholders at the Meeting have been approved by the shareholders by the requisite majority in accordance with the Israeli Companies Law, 5759-1999.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.

Date: May 26, 2016	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer